Question
Does the monoclonal antibody sarilumab facilitate the tapering of glucocorticoid therapy in patients with polymyalgia rheumatica?
Conclusion
Giving patients with PMR sarilumab twice monthly for 1 year allows an accelerated tapering regimen that greatly reduces the cumulative steroid dose and increases the likelihood of remission (which was low in both groups). Neutropenia, diarrhea, and arthralgia were common adverse effects. The annual drug cost is estimated to be $18,400. The cost per additional sustained response is more than $90,000, and it is unclear what the value is of the lower cumulative dose of prednisone.
Recent Posts
- Question of the Week
- Is In-person and remote physical therapy are equally effective for Chronic Knee Pain?
- The risk of breast cancer overdiagnosis is high for older women
- Severe hypocalcemia with denosumab therapy in dialysis-treated patients
- Sarilumab increases remission, decreases steroid dose in polymyalgia rheumatica taper, but at a high cost (SAPHYR)